Scientists shed light on a sleep peptide involved in Alzheimer’s

An MCH axon in the brain of a mouse model of Alzheimer's disease

Leuven, 17 May 2023 - In the early stages of Alzheimer’s disease, people exhibit cognitive stability despite the presence of toxic proteins and neuronal hyperactivity in their brains. Researchers at the VIB-KU Leuven Center for Brain & Disease Research have uncovered early alterations in a brain region that controls neuron network activity and sleep. These findings open up exciting avenues for further research into the disease.

Most people are familiar with the devastating effects of Alzheimer's disease. However, many are not aware that the symptoms and underlying biology of Alzheimer's don't take place suddenly but instead progress over a long time.

One of the earliest stages of Alzheimer's is the prodromal phase. While the classic behavioral hallmarks of the disease may not be present during this stage, many people will experience other, more subtle differences, such as sleep disturbances. The prodromal phase is characterized by markers of the disease in the brain, such as a build-up of toxic proteins and neuron network hyperactivity.

Despite these physiological changes, cognition remains largely intact during the prodromal period of Alzheimer's disease, which strongly suggests the existence of homeostatic mechanisms that keep the brain functioning. These mechanisms are not yet well understood, although it is known that they are active during sleep and that they drive a net decrease in the strength and rate of neuron network excitation. Scientists have recently been studying the what, where, and how of this homeostatic system, the findings of which were published in Nature Neuroscience.

"Using a mouse model of Alzheimer's disease, we discovered that these homeostatic mechanisms are activated in the CA1 region, which is part of the hippocampus, a region of the brain important for learning and memory," Sara Calafate, one of the project leads, explains.
Joris de Wit, Sara Calafate, and Bart De Strooper

The interdisciplinary research team of neuroscientists, electrophysiologists, and pathologists – spanning labs and facilities across Belgium, Portugal, Israel, Switzerland, and the UK – found melanin-concentrating hormone (MCH) to be a key mechanism in the homeostatic system, harmonizing neuron network hyperactivity in the hippocampus.

"It was already known that neurons containing MCH reside in a small system of neurons located deep inside the brain called the lateral hypothalamic area. Despite its small size, this system is, in fact, a key player in the brain, with neurons that connect all the way to the CA1 region of the hippocampus." Joris de Wit, another co-lead based at the VIB-KU Leuven Center for Brain & Disease Research, highlights. "These MCH-expressing neurons are also known to be active during sleep and are involved in hippocampus-dependent memory. They're therefore a natural target of study for the prodromal phase of Alzheimer's. Indeed, we found that in both our Alzheimer's mouse model and in human brain tissue of Alzheimer patients, the connections of MCH neurons are damaged."

Promisingly, these scientists also found that by introducing an MCH peptide (a short string of amino acids, the building blocks of proteins) into hippocampal brain slices from an Alzheimer’s disease mouse model, they could reverse the hyperactivity in the hippocampal neuron network.

"All in all, our findings show the MCH system to be vulnerable in the early stages of Alzheimer's disease," Bart De Strooper – another study co-lead – shares. Bart De Strooper has been studying Alzheimer's at the VIB-KU Leuven Center for Brain & Disease research for over 30 years, in addition to acting as Scientific Director of the UK Dementia Research Institute. "In addition, the lateral hypothalamic area has not been previously demonstrated to be involved in the underlying neurobiology of Alzheimer's disease. This provides exciting avenues for research into the disease moving forward."

An MCH axon residing in the brain of a mouse model of Alzheimer's disease

Publication

Early alterations in the MCH system link aberrant neuronal activity and sleep disturbances in a mouse model of Alzheimer’s disease. Calafate, et al. Nature Neuroscience, 2023. https://doi.org/10.1038/s41593-023-01325-4


India Jane Wise

India Jane Wise

Science Communications Expert, VIB

About the VIB-KU Leuven Center for Brain & Disease Research

Scientists at the VIB-KU Leuven Center for Brain & Disease study how brain cells are organized and how they communicate with each other. These mechanisms reveal and provide insights into what goes wrong in brain diseases such as Alzheimer's, Parkinson's, ALS, and dystonia. This basic work should ultimately lead to new drugs for use against these currently incurable diseases.

Share

Latest stories

Website preview
New lung cancer model reveals how tumor location shapes the immune response
Brussels, 27 April 2026 – Researchers at VIB and VUB have developed a powerful new way to study how the immune system behaves inside lung tumors. By combining a patient-relevant mouse model with single-cell technologies, the team provides one of the most comprehensive immune maps to date of lung adenocarcinoma, which is the most common subtype of lung cancer. Their work appears in Nature Communications.
press.vib.be
Website preview
Molecular keyhole sheds light on pain and epilepsy
Leuven, 21 April 2026 – Researchers at VIB, VUB, and KU Leuven have identified a tiny binding site, a molecular ’keyhole’, in the TRPM3 ion channel, a crucial sensor in pain signaling. TRPM3 is also linked to rare neurodevelopmental disorders and epilepsy. In a recent study published in Nature Communications, the researchers found that even the slightest change in this keyhole can radically switch the channel’s behavior, explaining how certain mutations can flip the effects of drugs.
press.vib.be
Website preview
Designing better membrane proteins by embracing imperfection
Brussels, 14 April 2026 — Scientists at the VIB–VUB Center for Structural Biology have uncovered a counterintuitive principle that could reshape how membrane proteins are designed from scratch: sometimes, making a protein less stable helps it fold correctly. In a study published in Proceedings of the National Academy of Sciences (PNAS), researchers demonstrate that introducing carefully placed ‘imperfections’, a strategy known as negative design, enables synthetic membrane proteins to fold and assemble efficiently in artificial membranes.
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be